Clinical trials
Recent articles
Expediting clinical trials for profound autism: Q&A with Matthew State
Aligning Research to Impact Autism, a new initiative funded by the Sergey Brin Family Foundation, wants to bring basic science discoveries to the clinic faster.

Expediting clinical trials for profound autism: Q&A with Matthew State
Aligning Research to Impact Autism, a new initiative funded by the Sergey Brin Family Foundation, wants to bring basic science discoveries to the clinic faster.
What’s next for brain-directed gene therapy after death in Neurogene trial
The incident highlights that viral vectors can trigger deadly immune responses even when delivered directly to the nervous system.

What’s next for brain-directed gene therapy after death in Neurogene trial
The incident highlights that viral vectors can trigger deadly immune responses even when delivered directly to the nervous system.
Former Columbia University psychiatrist committed research misconduct, says federal watchdog
Bret Rutherford, whose research was halted following a suicide in a clinical trial, falsely reported participant eligibility, according to the U.S. Office of Research Integrity.

Former Columbia University psychiatrist committed research misconduct, says federal watchdog
Bret Rutherford, whose research was halted following a suicide in a clinical trial, falsely reported participant eligibility, according to the U.S. Office of Research Integrity.
Building an autism research registry: Q&A with Tony Charman
A purpose-built database of participants who have shared genomic and behavioral data could give clinical trials a boost, Charman says.

Building an autism research registry: Q&A with Tony Charman
A purpose-built database of participants who have shared genomic and behavioral data could give clinical trials a boost, Charman says.
Leveraging the power of community to strengthen clinical trials for rare genetic syndromes
Families can become not only participants but champions of these research efforts.

Leveraging the power of community to strengthen clinical trials for rare genetic syndromes
Families can become not only participants but champions of these research efforts.
FDA describes ‘objectionable conditions’ at New York State Psychiatric Institute
The facility’s institutional review board failed to report a 2021 incident and “serious and ongoing noncompliance” by a principal investigator, according to a letter released by the federal agency this week.

FDA describes ‘objectionable conditions’ at New York State Psychiatric Institute
The facility’s institutional review board failed to report a 2021 incident and “serious and ongoing noncompliance” by a principal investigator, according to a letter released by the federal agency this week.
Seen and heard: The Transmitter’s top multimedia stories in 2023
Our audio, video and photo highlights from the past year help to transport readers into scientists’ lives and research, and the lives of their study participants.

Seen and heard: The Transmitter’s top multimedia stories in 2023
Our audio, video and photo highlights from the past year help to transport readers into scientists’ lives and research, and the lives of their study participants.
Year in Review: Spectrum’s best in 2023
Here are five must-reads from our coverage of autism research over the past 12 months.

Year in Review: Spectrum’s best in 2023
Here are five must-reads from our coverage of autism research over the past 12 months.
Standout neuroscience news in 2023
Did you miss any of our favorite stories from the past year? Revisit them here.

Standout neuroscience news in 2023
Did you miss any of our favorite stories from the past year? Revisit them here.
Unmasking Alzheimer’s disease
People with early-onset Alzheimer’s disease describe why they enrolled in clinical trials through the Dominantly Inherited Alzheimer Network (DIAN), in a new book of portrait photography.

Unmasking Alzheimer’s disease
People with early-onset Alzheimer’s disease describe why they enrolled in clinical trials through the Dominantly Inherited Alzheimer Network (DIAN), in a new book of portrait photography.
Explore more from The Transmitter
Null and Noteworthy: Learning theory validated 20 years later
The first published paper from the EEGManyLabs replication project nullifies a null result that had complicated a famous reinforcement learning theory.

Null and Noteworthy: Learning theory validated 20 years later
The first published paper from the EEGManyLabs replication project nullifies a null result that had complicated a famous reinforcement learning theory.
Neuroscientist Gerry Fischbach, in his own words
In 2023, I had the privilege of sitting down with Gerry over the course of several days and listening as he told the story of his life and career—including stints as dean or director of such leading institutions as Columbia University and NINDS—so that we could record it for posterity.

Neuroscientist Gerry Fischbach, in his own words
In 2023, I had the privilege of sitting down with Gerry over the course of several days and listening as he told the story of his life and career—including stints as dean or director of such leading institutions as Columbia University and NINDS—so that we could record it for posterity.
Amina Abubakar translates autism research and care for Kenya
First an educator and now an internationally recognized researcher, the Kenyan psychologist is changing autism science and services in sub-Saharan Africa.

Amina Abubakar translates autism research and care for Kenya
First an educator and now an internationally recognized researcher, the Kenyan psychologist is changing autism science and services in sub-Saharan Africa.